CARsgen Therapeutics Holdings Limited
2171.HK
Hong Kong Stock Exchange15.49
HKD
+0.93
- -
CARsgen Therapeutics Holdings Limited
2171.HK
(Hong Kong Stock Exchange)
Recent
price
15.49
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CARsgen Therapeutics Holdings Limited (2171.HK) is a biopharmaceutical company that discovers, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies, solid tumors and autoimmune diseases. The company maintains an integrated cell therapy platform encompassing target discovery, antibody development, preclinical research, clinical trials and commercial-scale manufacturing with proprietary technologies including THANK-uCAR for allogeneic CAR-T cells, CARcelerate for rapid production, CycloCAR to enhance solid tumor efficacy and LADAR for precise targeting. Core products comprise the fully human autologous BCMA CAR-T therapy zevor-cel (CT053, zevorcabtagene autoleucel), approved by China's NMPA in February 2024 for relapsed/refractory multiple myeloma after at least three prior lines of therapy; satri-cel (CT041, satricabtagene autoleucel), the first Claudin18.2-targeted CAR-T for solid tumors with NDA accepted by NMPA under priority review and breakthrough therapy designation for advanced gastric/gastroesophageal junction adenocarcinoma; CT071, a GPRC5D-targeted CAR-T using CARcelerate platform; CT011, a glypican-3-targeted CAR-T for hepatocellular carcinoma; and allogeneic candidates CT0590 (BCMA/NKG2A-targeted), CT0596 (BCMA-targeted with positive clinical data in multiple myeloma and plasma cell leukemia), KJ-C2219, KJ-C2320, KJ-C2114 and KJ-C2526 targeting various hematological and solid tumors. Operations span China and the United States with GMP facilities in Shanghai, Jinshan, RTP North Carolina and Bellaire Texas; founded in 2014, CARsgen is headquartered at 1F Building 2 No 466 Yindu Road Xuhui District Shanghai China. Recent developments include a February 2025 strategic partnership with Zhuhai Hengqin SB Xinchuang via its managed fund subscribing RMB80 million for 8% equity in subsidiary UCARsgen Biotech to accelerate allogeneic CAR-T commercialization in mainland China; NMPA priority approval in November 2025 of Claudin18.2 companion diagnostic kit for satri-cel; positive November 2025 clinical data for allogeneic CAR-T products CT0596 and CT1190B; October 2025 premarket approval application acceptance for the companion diagnostic; September 2025 long-term follow-up results for zevor-cel; and October 2025 preliminary satri-cel data in pancreatic cancer adjuvant therapy at ESMO Congress. Commercial rights for zevor-cel in mainland China rest with Huadong Medicine and in South Korea with HK Inno.N.
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit